

# ORIGINAL ARTICLES, REVIEWS AND EDITORIALS IN REFEREED JOURNALS

**Carlo Patrono**

- 1) Serra A, Sargentini S, Patrono C, Ferrara A, Laghi V. 45, X, G- , Phl cell line in bone marrow and blood of CML affected male. **Ann Genet**, 13:239-243, 1970.
- 2) Patrono C. Radioimmunoassay of Prostaglandin F<sub>2α</sub> in unextracted human plasma. **J Nucl Biol Med**, 17:25-29, 1973.
- 3) Pozzuoli R, Musiani P, Arru E, Patrono C, Piantelli M. Echinococcus granulosus: evaluation of purified antigens immunoreactivity. **Exp Parasitol**, 35:52-60, 1974.
- 4) La Torre E, Patrono C, Fortuna A, Grossi-Belloni D. Role of Prostaglandin F<sub>2α</sub> in human cerebral vasospasm. **J Neurosurg**, 41:293-299, 1974.
- 5) Patrono C, Ciabattoni G, Grossi-Belloni D. *In vitro* and *in vivo* inhibition of Prostaglandin synthesis by Fenoprofen, a non steroid anti-inflammatory drug. **Pharmacol Res Commun**, 6:509-518, 1974.
- 6) Patrono C, Grossi-Belloni D, Ciabattoni G, Serra GB, La Torre E, Bombardieri S, Mancuso S, Gorga C. Radioimmunoassay measurement of F Prostaglandins in human body fluids. **Horm Metab Res Supplement series 5**:190-195, 1974.
- 7) Greco AV, Ghirlanda G, Patrono C, Fedeli G, Manna R. Behaviour of pancreatic glucagon, insulin and GHG in liver cirrhosis, after arginine and i.v. glucose. **Acta Diabetol Lat**, 11:330-339, 1974.
- 8) Patrono C, Ciabattoni G, Grossi-Belloni D. Release of Prostaglandin F<sub>1α</sub> and F<sub>2α</sub> from superfused platelets: quantitative evaluation of the inhibitory effects of some Aspirin-like drugs. **Prostaglandins**, 9:557-568, 1975.
- 9) Togna G, Gandolfi C, Andreoni A, Fumagalli A, Passarotti C, Faustini F, Patrono C. Inhibition of human platelet aggregation by stable analogs of prostacyclin. **Pharmacol Res Commun**, 9:909-916, 1977.
- 10) Patrono C, Ciabattoni G, Venuti A, Pugliese F, Schiavino D, Patriarca G. Aspirin intolerance: unaltered susceptibility of platelet cyclooxygenase to inhibition by aspirin in vitro. **J Allergy Clin Immunol**, 62:271-275, 1978.
- 11) Ciabattoni G, Pugliese F, Spaldi M, Cinotti GA, Patrono C. Radioimmunoassay measurement of prostaglandins E<sub>2</sub> and F<sub>2α</sub> in human urine. **J Endocrinol Invest**, 2:173-182, 1979.
- 12) Ciabattoni G, Pugliese F, Cinotti GA, Stirati G, Ronci R, Castrucci G, Pierucci A, Patrono C. Characterization of furosemide-induced activation of the renal prostaglandin system. **European J Pharmacol**, 60:181-187, 1979.
- 13) Patrono C, Wennmalm A, Ciabattoni G, Nowak J, Pugliese F, Cinotti GA. Evidence for an extra-renal origin of urinary prostaglandin E<sub>2</sub> in healthy men. **Prostaglandins**, 18:623-629, 1979.

- 14) Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low-dose aspirin and inhibition of thromboxane B<sub>2</sub> production in healthy subjects. **Thromb Res**, 17:317-327, 1980.
- 15) Patrono C, Pugliese F. The involvement of arachidonic acid metabolism in the control of renin release. **J Endocrinol Invest**, 3:193-201, 1980.
- 16) Caruso I, Moro E, Patrono C, Sacchetti G, Tamassia V, Tosolini GP. Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis. **Scand J Rheumatol**, 9:123-126, 1980.
- 17) Patrono C, Pugliese F, Ciabattoni G, Di Blasi S, Pierucci A, Cinotti GA, Maseri A, Chierchia S. Prostacyclin does not affect insulin secretion in humans. **Prostaglandins**, 21:379-385, 1981.
- 18) Bombardieri S, Cattani P, Ciabattoni G, Di Munno O, Pasero GP, Patrono C, Pinca E, Pugliese F. The synovial prostaglandin system in chronic inflammatory arthritis. Differential effects of steroidal and nonsteroidal antiinflammatory drugs. **Br J Pharmacol**, 73:893-901, 1981.
- 19) Patrono C, Rotella CM, Toccafondi R, Aterini S, Pinca E, Tanini A, Zonefrati R. Prostacyclin stimulates the adenylate cyclase system of human thyroid tissue. **Prostaglandins**, 22:105-115, 1981.
- 20) Edlund A, Bomfin W, Kaijser L, Olin C, Patrono C, Pinca E, Wennmalm A. Pulmonary formation of prostacyclin in man. **Prostaglandins**, 22:323-332, 1981.
- 21) Chierchia S, Patrono C, Crea F, Ciabattoni G, De Caterina R, Cinotti GA, Distanto A, Maseri A. Effects of intravenous prostacyclin in variant angina. **Circulation**, 65:470-477, 1982.
- 22) Patrono C, Pugliese F, Ciabattoni G, Patrignani P, Maseri A, Chierchia S, Cinotti GA, Simonetti BM, Pierucci A, Peskar BA. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. **J Clin Invest**, 69:231-239, 1982.
- 23) Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. **J Clin Invest**, 69:1366-1372, 1982.
- 24) Chierchia S, De Caterina R, Crea F, Patrono C, Maseri A. Failure of thromboxane A<sub>2</sub> blockade to prevent attacks of vasospastic angina. **Circulation**, 66:702-705, 1982.
- 25) Edlund A, Bomfin W, Kaijser L, Olin C, Patrono C, Pinca E, Wennmalm A. Cardiac formation of prostacyclin during cardioplegia in man. **Prostaglandins**, 24:5-19, 1982.
- 26) Aehringhaus U, Wolbing RH, Konig W, Patrono C, Peskar BM, Peskar BA. Release of Leukotriene C<sub>4</sub> from human polymorphonuclear leucocytes as determined by radioimmunoassay. **FEBS letters**, 146:111-114, 1982.
- 27) Eriksson S, Hagenfeldt L, Law D, Patrono C, Pinca E, Wennmalm A. Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide stimulated cerebral blood flow in man. **Acta Physiol Scand**, 117:203-211, 1983.
- 28) Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, Day JS, Smith WL, Pinca E, Patrignani P, Patrono C. Reduced platelet thromboxane formation in uremia. Evidence for a

functional cyclooxygenase defect. **J Clin Invest**, 71:762-768, 1983.

29) FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. **Circulation**, 67:1174-1177, 1983.

30) Edlund A, Fredholm BB, Patrignani P, Patrono C, Wennmalm A, Wennmalm M. Release of two vasodilators -adenosine and prostacyclin- from isolated rabbit hearts during controlled hypoxia. **J Physiol (Lond)**, 340:487-501, 1983.

31) Patrignani P, Filabozzi P, Catella F, Pugliese F, Patrono C. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin endoperoxide metabolism. **J Pharmacol Exp Ther**, 228:472-477, 1984.

32) Ciabattoni G, Cinotti GA, Pieurucci A, Simonetti BM, Manzi M, Pugliese F, Barsotti P, Pecci G, Taggi F, Patrono C. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. **N Engl J Med**, 310:279-283, 1984.

33) Patrono C, Preston FE, Vermeylen J. Platelet and vascular arachidonic acid metabolites. Can they help detect a tendency towards thrombosis? **Br J Haematol**, 57:209-212, 1984.

34) Patrono C. Tissue-selective inhibition of prostaglandin and thromboxane synthesis in man: investigative and therapeutic implications. **Clin Physiol**, 4:443-447, 1984.

35) Lindgren JA, Hokfelt T, Dahlen S-E, Patrono C, Samuelsson B. Leukotrienes in the rat central nervous system. **Proc Natl Acad Sci USA**, 81:6212-6216, 1984.

36) Hulting A-L, Lindgren J-A, Hokfelt T, Heidvall K, Eneroth P, Werner S, Patrono C, Samuelsson B. Leukotriene C<sub>4</sub> stimulates LH secretion from rat pituitary cells *in vitro*. **Euro J Pharmacol**, 106:459-460, 1984.

37) De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L'Abbate A, Donato L, Patrignani P, Filabozzi P, Patrono C. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. **Am J Cardiol**, 55:589-590, 1985.

38) Patrono C, Ciabattoni G, Patrignani P, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. **Circulation**, 72: 1177-1184, 1985.

39) Alessandrini P, Avogaro P, Bittolo Bon G, Patrignani P, Patrono C. Physiologic variables affecting thromboxane B<sub>2</sub> production in human whole blood. **Thromb Res**, 37:1-8, 1985.

40) Hulting AL, Lindgren JA, Hokfelt T, Eneroth P, Werner S, Patrono C, Samuelsson B. Leukotrienes C<sub>4</sub> as a mediator of luteinizing hormone release from rat anterior pituitary cells. **Proc Natl Acad Sci USA**, 82:3834-3838, 1985.

41) Edlund A, Berglund B, Van Dorne D, Kaijser L, Nowak J, Patrono C, Sollevi A, Wennmalm A. Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. **Circulation**, 71:1113-1120, 1985.

42) De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L'Abbate A, Donato L, Patrignani P, Filabozzi P, Patrono C. Low-dose aspirin in patients recovering from myocardial

infarction. Evidence for a selective inhibition of thromboxane-related platelet function. **Eur Heart J**, 6:409-417, 1985.

43) De Caterina R, Giannessi D, Boem A, Bernini W, Battaglia D, Michelassi C, Dell'Amico F, L'Abbate A, Patrignani P, Patrono C. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. **Thromb Haemostas**, 54:528-532, 1985.

44) Patrono C, Ciabattoni G, Remuzzi G, Gotti E, Bombardieri S, Di Munno O, Tartarelli G, Cinotti GA, Simonetti BM, Pierucci A. Functional significance of renal prostacyclin and thromboxane A<sub>2</sub> production in patients with Systemic Lupus Erythematosus. **J Clin Invest**, 76:1011-1018, 1985.

45) Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal man. **J Clin Invest**, 77:590-594, 1986.

46) Lawson JA, Patrono C, Ciabattoni G, FitzGerald GA. Long lived enzymatic metabolites of thromboxane B<sub>2</sub> in the human circulation. **Anal Biochem**, 155:198-205, 1986.

47) Patrono C. Aspirin for the prevention of coronary thrombosis: current facts and perspectives. **Eur Heart J**, 7:454-459, 1986.

48) Patrono C, Pierucci A. Renal effects of nonsteroidal anti inflammatory drugs in chronic glomerular disease. **Am J Med**, 81:71-83, 1986.

49) Bertani T, Livio M, Macconi D, Morigi M, Bisogno G, Patrono C, Remuzzi G. Platelet-activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. **Kidney Int**, 31:1248-1256, 1987.

50) Ciabattoni G, Boss AH, Patrignani P, Catella F, Simonetti BM, Pierucci A, Pugliese F, Filabozzi P, Patrono C. Effects of sulindac on renal and extrarenal eicosanoid synthesis. **Clin Pharmacol Ther**, 41:380-383, 1987.

51) Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. **Kidney Int**, 32:1-12, 1987.

52) Ciabattoni G, Maclouf J, Catella F, FitzGerlad GA, Patrono C. Radioimmunoassay of 11-dehydro-thromboxane B<sub>2</sub> in human plasma and urine. **Biochim Biophys Acta**, 918:293-397, 1987.

53) Chierchia S, Patrono C. The role of platelet and vascular eicosanoids in the pathophysiology of ischaemic disease. **Fed Proc**, 46:81-88, 1987.

54) Pierucci A, Simonetti BM, Pecci G, Mavrikakis G, Feriozzi S, Cinotti GA, Patrignani P, Ciabattoni G, Patrono C. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. **N Engl J Med**, 320:421-425, 1989.

55) Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B<sub>2</sub> to urinary 11-dehydro-thromboxane B<sub>2</sub> in man. **Biochim Biophys Acta**, 992:66-70, 1989.

56) Patrignani P, Morton H, Cirino M, Lord A, Charette L, Gillard J, Rokach J, Patrono C. Fractional conversion of thromboxane A<sub>2</sub> and B<sub>2</sub> to urinary 2,3-dinor-thromboxane B<sub>2</sub> and 11-dehydro-thromboxane B<sub>2</sub> in the cynomolgus monkey. **Biochim Biophys Acta**, 992:71-77, 1989.

- 57) Macconi D, Benigni A, Morigi M, Ubiali A, Orisio S, Livio M, Perico N, Bertani T, Remuzzi G, Patrono C. Enhanced glomerular thromboxane A<sub>2</sub> mediates some pathophysiologic effects of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials. **J Lab Clin Med**, 113:594-560, 1989.
- 58) Benigni A, Chiabrando C, Perico N, Fanelli R, Patrono C, Fitzgerald G, Remuzzi G. Renal metabolism and urinary excretion of thromboxane B<sub>2</sub> in the rat. **Am J Physiol**, 257:F77-85, 1989.
- 59) Nicosia S, Patrono C. Eicosanoid biosynthesis and action: novel opportunities for pharmacologic intervention. **FASEB J**, 3:1941-1948, 1989.
- 60) Patrono C. Measurement of thromboxane biosynthesis in man. **Eicosanoids**, 2:249-251, 1989.
- 61) Ferrario RG, Foukles R, Salvati P, Patrono C. Hemodynamic and tubular effects of endothelin and thromboxane in the isolated perfused rat kidney. **Eur J Pharmacol**, 171:127-134, 1989.
- 62) Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. **Trends Pharmacol Sci**, 10:453-458, 1989.
- 63) Vejar M, Fragasso G, Hackett D, Lipkin PD, Maseri A, Born GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. **Thromb Haemost**, 63:163-168, 1990.
- 64) Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type-II diabetes mellitus. **N Engl J Med**, 322:1769-1774, 1990.
- 65) Salvati P, Ferti C, Ferrario RG, Lamberti E, Duzzi L, Bianchi G, Remuzzi G, Perico N, Benigni A, Braidotti P, Coggi G, Pugliese F, Patrono C. Role of enhanced glomerular synthesis of thromboxane A<sub>2</sub> in progressive kidney disease. **Kidney Int**, 38:447-452, 1990.
- 66) De Caterina R, Boem A, Gazzetti P, Sicari R, Giannessi D, Ciabattoni G, Patrono C. Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. **Thromb Res**, 60:169-175, 1990.
- 67) Patrignani P, Volpi D, Ferrario R, Romanzini L, Patrono C. Effects of racemic-, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. **Eur J Pharmacol**, 191:83-88, 1990.
- 68) Salvati P, Dho L, Ferrario RG, Parenti P, Vicedomini G, Chierchia S, Patrono C. Proarrhythmic activity of intracoronary endothelin in the dog: relation to the site of administration and to changes in regional flow. **J Cardiovasc Pharmacol**, 17:1007-1014, 1991.
- 69) Fabbri MS, Vitale A, Patrono C, Zamai M, Vaghi F, Caiolfa V, Monaco L, Benatti L. Heterologous *in vivo* processing of human preproendothelin-1 into bioactive peptides. **Proc Natl Acad Sci USA**, 88:8939-8943, 1991.
- 70) Patrignani P, Del Maschio A, Bazzoni G, Hernandez A, Modica R, Montesanti L, Volpi D, Patrono C, Dejana E. Inactivation of Endothelin by polymorphonuclear leukocytes-derived lytic enzymes. **Blood**, 78:2715-2720, 1991.

- 71) Tarugi P, Nicolini S, Albertazzi L, Calandra S, Salvati P, Ferti C, Patrono C. Dyslipoproteinemia in an inbred rat strain with spontaneous chronic progressive nephrotic syndrome. **J Lipid Res**, 32:1675-1687, 1991.
- 72) Remuzzi G, FitzGerald GA, Patrono C. Thromboxane synthesis and action within the kidney. **Kidney Int**, 41:1483-1493, 1992.
- 73) Davì G, Notarbartolo A, Catalano I, Averna M, Barbagallo C, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. **Circulation**, 85:1792-1798, 1992.
- 74) Maclouf J, Antoine C, De Caterina R, Sicari R, Murphy RC, Patrignani P, Loizzo S, Patrono C. Entry rate and metabolism of leukotriene C<sub>4</sub> into the vascular compartment in healthy subjects. **Am J Physiol**, 263:H-244-249, 1992.
- 75) Landolfi R, Ciabattoni G, Patrignani P, Castellana MAL, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera. Evidence for aspirin-suppressable platelet activation *in vivo*. **Blood**, 80:1965-1971, 1992.
- 76) Salvati P, Dho L, Calabresi M, Rosa B, Patrono C. Evidence for a direct vasoconstrictor effect of Big Endothelin-1 in the rat kidney. **Eur J Pharmacol**, 221:267-273, 1992.
- 77) Zamai M, Menziani MC, De Benedetti PG, Patrono C, Caiolfa VR. Sequence-directed peptide inhibitor for human big Endothelin. **Med Chem Res**, 2:208-212, 1992.
- 78) Patrignani P, Daffonchio L, Hernandez A, De Caterina R, Pelosi G, Patrono C. Release of contracting autocoids by aortae of normal and atherosclerotic rabbits. **J Cardiovasc Pharmacol**, 20:S208, 1992.
- 79) Koudstaal PJ, Ciabattoni G, Van Gijn J, Nieuwenhuis HK, De Groot P, Sixma JJ, Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. **Stroke**, 24:219-223, 1993.
- 80) Ciabattoni G, Ujang S, Sritara P, Andreotti F, Davies G, Simonetti BM, Patrono C, Maseri A. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterisation or coronary angioplasty. **J Am Coll Cardiol**, 21:1377-1381, 1993.
- 81) Fabbrini MS, Vitale A, Pedrazzini E, Nitti G, Zamai M, Tamburin M, Caiolfa VR, Patrono C, Benatti L. *In vivo* expression of mutant preproendothelins: hierarchy of processing events but no strict requirement of Trp-Val at the processing site. **Proc Natl Acad Sci USA**, 90:3923-3927, 1993.
- 82) Patrignani P, Modica R, Bertolero F, Patrono C. Differential effects of leukotriene C<sub>4</sub> on endothelin-1 and prostacyclin release by cultured vascular cells. **Pharmacol Res**, 27:281-285, 1993.
- 83) Créminon C, Frobert Y, Habib A, Maclouf J, Patrono C, Pradelles P, Grassi J. Enzyme immunometric assay for endothelin using tandem monoclonal antibodies. **J Immunol Methods**, 162:179-192, 1993.
- 84) De Ferrari GM, Salvati P, Grossoni M, Ukmar G, Vaga L, Patrono C, Schwartz PJ. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacoline and oxotremorine in conscious dogs with a healed myocardial infarction. **J Am Coll Cardiol**, 21:283-290, 1993.

- 85) Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C, Mancini M. Abnormally high thromboxane A<sub>2</sub> biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. **J Clin Invest**, 92:1400-1406,1993.
- 86) Davì G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. **Arterioscler Thromb**, 13:1346-1349, 1993.
- 87) Patrono C, Davì G. Antiplatelet agents in the prevention of diabetic vascular complications. **Diabetes Metab Rev**, 9:177-188, 1993.
- 88) Van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, Van Gijn J, Koudstaal PJ. Evidence for episodic platelet activation in acute ischemic stroke. **Stroke**, 25:278-281; 1994.
- 89) Patrono C. Aspirin as an antiplatelet drug. **N Engl J Med**, 330: 1287-1294; 1994.
- 90) Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O, Patrono C. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis. **J Pharmacol Exp Ther**, 269: 238-245; 1994.
- 91) Landolfi R, De Candia E, Rocca B, Ciabattoni G, Antinori A, Masetti R, Patrono C. Effects of unfractionated and low molecular weight heparins on thromboxane biosynthesis "in vivo". **Thromb Haemost**, 72:942-946, 1994.
- 92) Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, Maclouf J, Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. **J Pharmacol Exp Ther**, 271:1705-1712, 1994.
- 93) Notarbartolo A, Davì G, Averna M, Barbagallo MB, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. **Arterioscler Thromb Vasc Biol**, 15:247-251, 1995.
- 94) Pugliese F, Ferrario RG, Ciavolella A, Tamburin M, Benatti L, Casini A, Patrono C, Salvati P. Growth abnormalities in cultured mesangial cells from rats with spontaneous glomerulosclerosis. **Kidney Int**, 47:106-113; 1995.
- 95) Salvati P, Lamberti E, Ferrario R, Ferrario RG, Scampini G, Pugliese F, Barsotti P, Patrono C. Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. **Kidney Int**, 47:1168-1175, 1995.
- 96) Mené P, Pugliese F, Patrono C. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. **Semin Nephrol**, 15:244-252, 1995.
- 97) Patrono C, Patrignani P, Rocca B, Landolfi R. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. **Thromb Haemost**, 74:396-400, 1995.

- 98) Barbui T, de Gaetano G, Finazzi G, Landolfi R, Marchioli R, Patrono C, Tognoni G and the Gruppo Italiano Studio Policitemia (GISP). Polycythemia Vera: the natural history of 1213 patients followed for 20 years. **Ann Intern Med**, 123:656-661, 1995.
- 99) Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. **Crit Rev Oncol Hematol**, 20:203-222, 1995.
- 100) Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono C, Patrignani P. Effects of nabumetone on prostanoid biosynthesis in man. **Clin Pharmacol Ther**, 58:335-341, 1995.
- 101) Wang Z, Ciabattoni G, Créminon C, Lawson, J, FitzGerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F<sub>2α</sub> excretion in man. **J Pharmacol Exp Ther**, 275:94-100, 1995.
- 102) Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, Di Gamberardino M, Cipollone F, Cuccurullo F, Patrono C, Patrignani P. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-inda none (L-745,337), on the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases **Br J Pharmacol**, 116:2429-2434, 1995.
- 103) Rocca B, Ciabattoni G, Tartaglione R, Cortellazzo S, Barbui T, Patrono C, Landolfi R. Increased thromboxane biosynthesis in essential thrombocythemia. **Thromb Haemost**, 74:1225-1230, 1995.
- 104) Hirsh J, Dalen J, Fuster V, Harker L, Patrono C, Roth G. Aspirin and other platelet active drugs: the relationship among dose, effectiveness and side effects. **Chest**, 108:247S-257S, 1995.
- 105) Patrono C, Roth GJ. Aspirin in ischemic cerebrovascular disease: how strong is the case for a different dosing regimen? **Stroke**, 27:756-760, 1996.
- 106) Patrignani P, Santini G, Panara MR, Sciulli MG, Greco A, Rotondo MT, di Gamberardino M, Maclouf J, Ciabattoni G, Patrono C. Induction of prostaglandin endoperoxide synthase-2 in human monocytes is associated with cyclooxygenase-dependent F<sub>2</sub>-isoprostane formation. **Br J Pharmacol**, 118:1285-1293,1996.
- 107) Landolfi R, Patrono C. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. **Leuk Lymphoma**, 22:83-86, 1996.
- 108) Patrono C. Unstable coronary artery disease: need for long-term antithrombotic treatment? **Cardiovasc Res**, 33:295-296,1997.
- 109) Barbui T, de Gaetano G, Finazzi G, Landolfi R, Marchioli R, Patrono C, Tognoni G and Gruppo Italiano Studio Policitemia Vera (GISP). Low-dose aspirin in Polycythemia Vera: a pilot study. **Br J Haematol**, 97:453-456,1997.
- 110) Davì G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia and hypertension, but not vascular disease per se, are associated with persistent platelet activation *in vivo*. Evidence derived from the study of peripheral arterial disease. **Circulation**, 96:69-75,1997.

- 111) Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. **Thromb Haemost**, 78:617-621,1997.
- 112) Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cucurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. **Circulation**, 96:1109-1116, 1997.
- 113) Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. **Arterioscler Thromb Vasc Biol**, 17:2309-2315, 1997.
- 114) Davì G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bittolo Bon G, Ciabattoni G, Patrono C. In vivo formation of 8-epi-prostaglandin F<sub>2α</sub> is increased in hypercholesterolemia. **Arterioscler Thromb Vasc Biol**, 17:3230-3235, 1997.
- 115) van Kooten F, Ciabattoni G, Patrono C, Dippel DWJ, Koudstaal PJ. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. **Stroke**, 28:1557-1563, 1997.
- 116) Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. **Thromb Haemostas**, 79:691-705, 1998.
- 117) Panara MR, Padovano R, Sciulli MG, Santini G, Renda G, Rotondo MT, Pace A, Patrono C, Patrignani P. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. **Clin Pharmacol Ther**, 63:672-681, 1998.
- 118) Patrono C, Collier B, Dalen JE, Fuster V, Gent M, Harker LB, Hirsh J, Roth G. Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. **Chest**, 114:470S-488S, 1998
- 119) Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. *In vivo* formation of 8-iso-prostaglandin F<sub>2α</sub> and platelet activation in diabetes mellitus. Effects of improved metabolic control and vitamin E supplementation. **Circulation**, 99:224-229, 1999
- 120) Van Kooten F, Ciabattoni G, Koudstaal PJ, Dippel DWJ, Patrono C. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. **Stroke**, 30:546-549, 1999
- 121) Panara MR, Renda G, Sciulli MG, Santini G, Rotondo MT, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. **J Pharmac Exp Ther**, 290:276-280,1999
- 122) Rocca B, Spain LM, Ciabattoni G, Patrono C, FitzGerald GA. Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. **J Immunol**, 162:4589-4597, 1999
- 123) Rocca B, Spain LM, Puré E, Langenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H-synthases 1 and 2 in T-cell development. **J Clin Invest**, 103:1469-1477,1999
- 124) Van Kooten F, Ciabattoni G, Koudstaal PJ, Grobbee DE, Kluft C, Patrono C. Increased thromboxane biosynthesis is associated with post-stroke dementia. **Stroke**, 30:1542-1547, 1999
- 125) Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. **Epidemiology**, 11:382-387, 2000.

- 126) Patrignani P, Panara MR, Tacconelli S, Seta F, Bucciarelli T, Ciabattoni G, Alessandrini P, Mezzetti A, Santini G, Sciulli MG, Cipollone F, Davì G, Gallina P, Bittolo Bon G, Patrono C. A randomized, placebo-controlled dose-finding study of the effect of vitamin E supplementation on F<sub>2</sub>-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. **Circulation**, 102:539-545, 2000.
- 127) Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Cucurullo F, Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. **Circulation**, 102:1007-1013, 2000
- 128) Ciabattoni G, Davì G, Collura M, Iapichino L, Pardo F, Ganci A, Romagnoli R, Maclouf J, Patrono C. *In vivo* lipid peroxidation and platelet activation in cystic fibrosis. **Am J Respir Crit Care Med**, 162:1195-1201, 2000.
- 129) Patrono C, Collier B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. **Chest**, 119:39S-63S, 2001
- 130) FitzGerald GA, Patrono C. The Coxibs, Selective Inhibitors of Cyclooxygenase-2. **N Engl J Med**, 345:433-442, 2001
- 131) Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. **J Clin Invest** 108:7-13, 2001.
- 132) Davì G, Di Minno G, Coppola A, Andria G, Cerbone AM, Falco A, Marchesani P, Bucciarelli T, Ciabattoni G, Patrono C. Oxidative stress and platelet activation in homozygous homocystinuria. **Circulation**, 104:1124-1128, 2001.
- 133) Santini G, Patrignani P, Sciulli MG, Seta F, Tacconelli S, Panara MR, Ricciotti E, Capone M, Patrono C. The human pharmacology of monocyte COX-2 inhibition by cortisol and synthetic glucocorticoids. **Clin Pharmacol Ther**, 70:475-483, 2001.
- 134) Thun MJ, Henly SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacological and clinical issues. **J Natl Cancer Inst**, 94: 252-262, 2002.
- 135) Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. **Proc Natl Acad Sci USA**, 99:7634-7639, 2002.
- 136) Cipollone F, Patrono C. Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury. **Arterioscler Thromb Vasc Biol**, 22:1516-1518, 2002.
- 137) Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopicolli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. **JAMA**, 288:2008-2014, 2002.
- 138) Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palestri S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Lechi Santoastaso C, Lechi

A, Morganti A, Patrono C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. **Circulation**, 106:2800-2805, 2002.

139) Baigent C, Patrono C. Selective cyclooxygenase-2 inhibitors, aspirin and cardiovascular disease: a re-appraisal. **Arthritis Rheum**, 48:12-20, 2003.

140) De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G, Landolfi R, Patrono C, Davì G. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. **J Thromb Haemostas**, 1:250-256, 2003.

141) Davì G, Chiarelli F, Pomicino MP, Santilli F, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus. Role of interleukin-6 and disease duration. **Circulation**, 107:3199-3203, 2003.

142) Patrono C. Aspirin Resistance: Definition, Mechanisms and Clinical Read-Outs. **J Thromb Haemostas**, 1:1710-1713, 2003.

143) Minuz P, Patrignani P, Gaino S, Seta F, Capone ML, Tacconelli S, Degan Maurizio, Faccini G, Fornasiero A, Talamini G, Tommasoli R, Arosio E, Lechi Santonastaso C, Lechi A, Patrono C. Determinants of platelet activation in human essential hypertension. **Hypertension**, 43:64-70, 2004.

144) Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. **N Engl J Med**, 350:114-124, 2004.

145) Patrono C, Bachmann F, Baigent C, Bode C, Charbonnier B, De Caterina R, Fitzgerald D, García Rodríguez LA, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Verheugt F, Vermylen J, Wallentin L. Expert Consensus Document on the Use of Antiplatelet Agents. **Eur Heart J**, 25: 166-81, 2004.

146) Davì G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. **Chemistry and Physics of Lipids**, 128:149-163, 2004.

147) Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis. **Arterioscler Thromb Vasc Biol**, 24:246-255, 2004.

148) Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P. Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. **Circulation**, 109:1468-1471, 2004.

149) Patrono C, Collier B, FitzGerald GA, Hirsh J, Roth G. Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. **Chest**, 126: 234S-264S, 2004.

150) Rocca B, Secchiero P, Celeghini C, Ranelletti FO, Ciabattoni G, Maggiano N, Habib A, Ricerca BM, Patrono C, Zauli G. Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. **Experimental Hematology**, 32:925-934, 2004.

151) Davì G, Neri M, Festi D, Falco A, Taraborelli T, Ciabattoni G, Cucurullo F, Patrono C. Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. **Arterioscler Thromb Vasc Biol**, 25:246-251, 2005

- 152) Patrono C, Falco A, Davì G. Isoprostane Formation and Inhibition in Atherothrombosis. **Curr Opin Pharmacol**, 5:198-203, 2005.
- 153) Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. **J Clin Oncol**, 23:2224-2232, 2005.
- 154) Davì G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. **Antioxid Redox Signal**, 7:256-268, 2005.
- 155) Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T. Acute leukaemia in polycythemia vera: an analysis of 1,638 patients enrolled in a prospective observational study. **Blood**, 105:2664-2670, 2005.
- 156) Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. **J Thromb Haemost**, 8:1597-1602, 2005.
- 157) Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. **N Engl J Med**, 353: 2373-83, 2005.
- 158) Born G, Patrono C. Antiplatelets Drugs. **Br J Pharmacol**, 147:S241-S251, 2006.
- 159) Santilli F, Davì G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoli G, Basili S, Patrono C. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. **J Am Coll Cardiol**, 47:391-397, 2006.
- 160) Ciabattoni G, Porreca E, Di Febbo C, Di Iorio A, Paganelli R, Bucciarelli T, Pescara L, Del Re L, Giusti C, Falco A, San A, Patrono C, Davì G. Determinants of platelet activation in Alzheimer's disease. **Neurobiol Aging**, 28:336-342, 2007.
- 161) Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. **BMJ**, 332:1302-1308, 2006.
- 162) Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Price TS, Patrono C, De Caterina R, Patrignani P. Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. **Clin Pharmacol Ther**, 80:264-274, 2006.
- 163) Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davì G. Insulin resistance as a determinant of platelet activation in obese women. **J Am Coll Cardiol**, 48:2531-2538, 2006
- 164) Landolfi R, Di Gennaro L, Novarese L, Patrono C. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. **Semin Thromb Hemost**, 32:251-259, 2006.
- 165) Patrono C. The PGH-synthase system and isozyme-selective inhibition. **J Cardiovasc Pharmacol**, 47:Suppl 1;S1-S6, 2006

- 166) Patrono C, Rocca B. Drug insight: aspirin resistance- fact or fashion? **Nat Clin Pract Cardiovasc Med**, 4:42-50, 2007.
- 167) Davi G, Patrono C. Platelet activation and atherothrombosis. **N Engl J Med**, 357:2482-2494, 2007.
- 168) Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8<sup>th</sup> Edition). **Chest** 133:199S-233S, 2008.
- 169) Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. **Arterioscler Thromb Vasc Biol**, 28:25S-32S, 2008.
- 170) Baigent C, Patrono C. Selective COX-2 inhibitors: where do we go from here? **Lancet**, 372:1712-3, 2008.
- 171) Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davi G, Patrono C. Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin is not Reflected Consistently by Platelet Function Assays. **J Am Coll Cardiol**, 53:667-77, 2009
- 172) Patrono C, Baigent C. Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges. **Mol Interv**, 9:31-9, 2009.
- 173) Patrono C, Rocca B. Nonsteroidal Antiinflammatory Drugs: Past, Present and Future. **Pharmacol Res**, 59:285-9, 2009.
- 174) Patrono C, Rocca B. Aspirin, 110 years later. **J Thromb Haemost**, 7(suppl.1):258-61, 2009.
- 175) ATT Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. **Lancet**, 373:1849-60, 2009.
- 176) Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, Ciabattoni G, Davi G, Patrono C, Rocca B. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-insensitive essential thrombocythemia: implications for antiplatelet therapy. **Blood**, 2009 Nov 3 epub.
- 177) Patrono C, Rocca B. The Future of Antiplatelet Therapy in Cardiovascular Disease. **Ann Rev Med**, 61:49-61, 2010.
- 178) Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P, Ganci A, Pulizzi N, Lattanzio S, Ciabattoni G, Consoli A, Lauro R, Patrono C, Davi G. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. **J Thromb Haemost**, 2010 *in press*.
- 179) Davi G, Santilli F, Patrono C. Nutraceuticals in diabetes and metabolic syndrome. **Cardio Therap**, 2010
- 180) Santilli F, Davi G, Basili S, Lattanzio S, Cavoni A, Guizzardi G, De Feudis L, Traisci G, Pettinella C, Minuz P, Meneguzzi A, Ciabattoni G, Patrono C. Thromboxane and Prostacyclin

Biosynthesis in Heart Failure of Ischemic Origin: Effects of Disease Severity and Aspirin Treatment. **J Thromb Haemost**, 2010 *in press*.